The Association between Apolipoprotein A-II and Metabolic Syndrome in Korean Adults: A Comparison Study of Apolipoprotein A-I and Apolipoprotein B.

Diabetes Metab J

Division of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea.

Published: February 2012

AI Article Synopsis

  • ApoA-II, which is the second-most common apolipoprotein in HDL, has an unclear role in metabolic syndrome (MetS) and may have conflicting effects on cardiovascular health.
  • The study analyzed data from 244 Korean adults and found that while apoB levels were higher and apoA-I levels were lower in those with MetS, apoA-II levels showed no significant differences or associations with MetS.
  • Despite the lack of correlation, the study suggests that apoA-II could have both harmful and protective roles in cardiovascular health, differing from the clear associations seen with apoA-I and apoB.

Article Abstract

Background: Apolipoprotein A-II (apoA-II) is the second-most abundant apolipoprotein in human high-density lipoprotein and its role in cardio metabolic risk is not entirely clear. It has been suggested to have poor anti-atherogenic or even pro-atherogenic properties, but there are few studies on the possible role of apoA-II in Asian populations. The aim of this study is to evaluate the role of apoA-II in metabolic syndrome (MetS) compared with apolipoprotein A-I (apoA-I) and apolipoprotein B (apoB) in Korean adults.

Methods: We analyzed data from 244 adults who visited the Center for Health Promotion in Pusan National University Yangsan Hospital for routine health examinations.

Results: The mean apoB level was significantly higher, and the mean apoA-I level was significantly lower, in MetS; however, there was no significant difference in apoA-II levels (30.5±4.6 mg/dL vs. 31.2±4.6 mg/dL, P=0.261). ApoA-II levels were more positively correlated with apoA-I levels than apoB levels. ApoA-II levels were less negatively correlated with homocysteine and high sensitivity C-reactive protein levels than apoA-I levels. The differences in MetS prevalence from the lowest to highest quartile of apoA-II were not significant (9.0%, 5.7%, 4.9%, and 6.6%, P=0.279). The relative risk of the highest quartile of apoA-II compared with the lowest quartile also was not significantly different (odds ratio, 0.96; 95% confidence interval, 0.95 to 1.04; P=0.956).

Conclusion: Compared with apoA-I (negative association with MetS) and apoB (positive association with MetS) levels, apoA-II levels did not show any association with MetS in this study involving Korean adults. However, apoA-II may have both anti-atherogenic and pro-atherogenic properties.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283827PMC
http://dx.doi.org/10.4093/dmj.2012.36.1.56DOI Listing

Publication Analysis

Top Keywords

apoa-ii levels
16
association mets
12
apoa-ii
10
levels
9
apolipoprotein a-ii
8
metabolic syndrome
8
korean adults
8
apolipoprotein a-i
8
anti-atherogenic pro-atherogenic
8
pro-atherogenic properties
8

Similar Publications

Association of Small HDL Subclasses with Mortality Risk in Chronic Kidney Disease.

Antioxidants (Basel)

December 2024

Division of Pharmacology, Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Neue Stiftingtalstraße 6, 8010 Graz, Austria.

High-density lipoproteins (HDL) exist in various subclasses, with smaller HDL particles possessing the highest anti-oxidative and anti-inflammatory properties. Understanding the role of these specific subclasses in chronic kidney disease (CKD) could provide valuable insights into disease progression and potential therapeutic targets. In the present study, we assessed HDL subclass composition in 463 patients with CKD stage 2-4 using nuclear magnetic resonance spectroscopy.

View Article and Find Full Text PDF

Alterations in LDL and HDL after an ischemic stroke associated with carotid atherosclerosis are reversed after 1 year.

J Lipid Res

December 2024

Cardiovascular Biochemistry Group, Institut de Recerca Sant Pau, (IR Sant Pau), Barcelona, Spain; CIBER of Diabetes and Metabolic Diseases (CIBERDEM), Spain. Electronic address:

Approximately 20% of ischemic strokes are attributed to the presence of atherosclerosis. Lipoproteins play a crucial role in the development of atherosclerosis, with LDL promoting atherogenesis and HDL inhibiting it. Therefore, both their concentrations and their biological properties are decisive factors in atherosclerotic processes.

View Article and Find Full Text PDF

Identifying biomarkers for Alzheimer's disease (AD) is crucial, due to its complex pathology, which involves dysfunction in lipid transport, contributing to neuroinflammation, synaptic loss, and impaired amyloid-β clearance. Nuclear magnetic resonance (NMR) is able to quantify and stratify lipoproteins. The study investigated lipoproteins in blood from AD patients, aiming to evaluate their diagnostic potential.

View Article and Find Full Text PDF

APOA2 increases cholesterol efflux capacity to plasma HDL by displacing the C-terminus of resident APOA1.

J Lipid Res

December 2024

Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA; Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH, USA; Department of Neurology, Oregon Health and Science University, Portland, OR, USA. Electronic address:

The ability of high-density lipoprotein (HDL) to promote cellular cholesterol efflux is a more robust predictor of cardiovascular disease protection than HDL-cholesterol levels in plasma. Previously, we found that lipidated HDL containing both apolipoprotein A-I (APOA1) and A-II (APOA2) promotes cholesterol efflux via the ATP-binding cassette transporter (ABCA1). In the current study, we directly added purified, lipid-free APOA2 to human plasma and found a dose-dependent increase in whole plasma cholesterol efflux capacity.

View Article and Find Full Text PDF

Effects of Catheter-Based Renal Denervation in Hypertension: A Systematic Review and Meta-Analysis.

Circulation

November 2024

Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Universität des Saarlandes, Homburg, Germany (D.V., L.L., M.B., F.M.).

Article Synopsis
  • A meta-analysis of randomized, sham-controlled trials was conducted to evaluate the effectiveness and safety of catheter-based renal denervation (RDN) in treating hypertension, involving 10 trials with a total of 2,478 patients.
  • The study found that RDN significantly lowered both 24-hour and office systolic and diastolic blood pressure compared to sham procedures, without a notable difference in complications or changes in renal function.
  • Overall, RDN appears to be a safe and effective method for reducing blood pressure in patients with hypertension, although significant variability was noted among the studies analyzed.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!